The MIP-1β increase was significantly lower in the treated groups compared to the BD group: Coversin group 1967 pg/mL (725–3210) (p < 0.0001), anti-CD14 group 839 pg/mL (53-1625) (p < 0.0001) and the dual treatment group 1721 pg/mL (72-3369) (p < 0.0001) (Fig. 2C). Here, CCL4 is linked to Behcet disease.